Skip to main content
  • Prospective, Multicenter, Historically Controlled Trial Comparing RhBMP-2 with Allograft in Single-Level Anterior Cervical Discectomy and Fusion

    Final Number:
    1304

    Authors:
    Kevin T. Foley MD FACS; Paul M. Arnold MD; Randall Dryer; John Kenneth Burkus; Carol Binns MA

    Study Design:
    Clinical Trial

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2013 Annual Meeting

    Introduction: Anterior cervical discectomy and fusion (ACDF) using rhBMP-2 with a PEEK implant and plate was compared with ACDF using allograft and plate in patients with symptomatic single-level cervical degenerative disc disease.

    Methods: Two hundred twenty-four patients were enrolled in a prospective IDE trial evaluating rhBMP-2/ACS in ACDF (0.6mg in 240 patients, 1.05mg in 4 patients). Clinical outcomes in rhBMP-2 patients were compared with those in 486 historical control allograft patients using propensity score technique to minimize bias. Assessments were completed preoperatively, at discharge, and during follow-up visits at 1.5, 3, 6, 12, and 24 months. Adverse events were recorded at every visit.

    Results: At 24 months, mean NDI improvement was greater in the rhBMP-2 group (37.1 points) than in the allograft group (31.4 points, p=0.002). Mean arm pain improvement was 11.0 points in the rhBMP-2 group compared with 9.7 points in the allograft group (p=0.031). The overall neurological success rate was significantly higher in the rhBMP-2 group (p<0.001). Neck pain and general health status (SF-36 PCS and MCS) were similar for both groups. The fusion rate in the rhBMP-2 group was 99.4% as determined by an independent radiology group. On reassessment of the allograft control patients, this same group found a fusion rate of 87.2% in contrast to the original fusion rate of 96%, which was assessed by a different radiology group. Cumulative adverse event rates were similar in the two groups; however, higher rates of some early adverse events--dysphagia, local swelling, and neck pain--were observed in the rhBMP-2 group. Through 24 months, the rate of subjects with any heterotopic ossification was significantly higher in the rhBMP-2 group (p<0.001).

    Conclusions: RhBMP-2 was effective in inducing fusion and improving arm pain and function. Higher rates of certain adverse events and heterotopic ossification were observed in the rhBMP-2 group.

    Patient Care: In patients undergoing surgery for single-level cervical disc disease, treatment with rhBMP-2 was effective in inducing fusion and improving pain and function.

    Learning Objectives: By the end of this presentation, participants should be able to compare the effectiveness of rhBMP-2 with that of allograft in anterior cervical discectomy and fusion and identify potential adverse events.

    References:

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy